COMMUNIQUÉS West-GlobeNewswire

Tris Pharma Earns 2026 Great Place To Work Certification™
14/10/2026
MONMOUTH JUNCTION, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Tris Pharma, Inc. is proud to be Certified™ by Great Place To Work®. The prestigious award is based entirely on what current employees say about their [...]
What’s More Space Age Than Spider Silk Spun by Kraig Labs’ Transgenic Silkworms?
14/10/2026
DENVER, Oct. 14, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) — Kraig Biocraft Laboratories (OTCQB: KBLB) shipped its first commercial spider silk yarn order, while its production operation set new records, and its [...]
NeOnc Strengthens Boardroom Firepower as Abu Dhabi Opens a New Path for Brain Cancer Drug Development
14/10/2026
DENVER, Oct. 14, 2026 (GLOBE NEWSWIRE) -- ( 247marketnews.com ) -- NeOnc Technologies Holdings (NASDAQ:NTHI) is strengthening its boardroom, while its clinical-development progress seeks to advance treatments for some [...]
UPDATE – MindBio Completes Manufacture of Next-Generation Voice AI Intoxication Detection Kiosk. Advances Software Validation & Testing In Preparation for First Commercial Pilot.
14/10/2026
VANCOUVER, British Columbia, Oct. 14, 2026 (GLOBE NEWSWIRE) -- MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) (the “ Company ” or “ MindBio ”), a biotechnology company advancing the [...]
Baylor Genetics Study Finds Genome Sequencing Identifies Genetic Diagnoses in Nearly One-Third of Children with Intellectual Disability and Developmental Delay
14/10/2026
HOUSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Baylor Genetics , a leading diagnostic genomics partner offering a full spectrum of comprehensive genetic tests and diagnostic services, today announced the publication of its [...]
New York City Biotech Startups Neion Bio and Barnwell Bio Partner to Advance Biomanufacturing and Biosecurity
14/10/2026
The collaboration brings together Neion Bio's egg-based biologics manufacturing platform and Barnwell Bio's metagenomic biosurveillance capabilities, while highlighting the growing New York City life sciences ecosystem [...]
Rakovina Therapeutics Secures Exclusivity on Optimized kt-5000 Lead Profile from Variational AI
14/10/2026
Agreement provides Rakovina exclusive access to its optimized kt-5000 target profile and extends AI-powered lead optimization through year-end at no additional cost VANCOUVER, British Columbia, Oct. 14, 2026 (GLOBE [...]
Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome
14/10/2026
– Company on track to initiate first-ever formal clinical trial in Peeling Skin Syndrome before year end – Orphan Drug designation milestone provides 10 years of market exclusivity for Peeling Skin Syndrome in Europe [...]
Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
14/10/2026
Establishes strategic commercial reach across the Middle East and North Africa, advancing Ocugen’s goal of enabling global patient access to potentially transformational gene therapies Expands access to a potential one- [...]
Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film
14/10/2026
Differentiated, portable buccal film would offer patients and caregivers an alternative to existing nasal and rectal seizure rescue treatments, a market opportunity that exceeds $450 million annually in the U.S. Patient [...]
Axogen, Inc. to Report Third Quarter 2026 Financial Results on October 28, 2026
14/10/2026
ALACHUA, Fla. and TAMPA, Fla., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, [...]
Parabilis Medicines Initiates Dose-Ranging Clinical Study of Zolucatetide in Familial Adenomatous Polyposis
14/10/2026
New dose-ranging cohort in FAP builds on compelling early clinical evidence observed with zolucatetide in patients with FAP and concomitant desmoid tumors Zolucatetide directly inhibits β-catenin:TCF, targeting the APC- [...]
Elion Therapeutics Expands Pipeline with Exclusive Global License to Inhaled Antifungal for Immunocompromised Patients
14/10/2026
- Phase 2-Ready EL777 Complements Company’s Turletricin Program Focused on Early Antifungal Treatment - Prophylaxis Is Critical for Cancer and Transplant Patients at High Risk of Invasive Fungal Infections BOSTON, Oct. [...]
Arexera Therapeutics, Formerly Atalanta Therapeutics, Unveils New Corporate Identity and Advances Huntington's Disease Franchise
14/10/2026
- Proprietary siRNA platforms, designed to enable robust and durable gene silencing throughout the brain, support a differentiated Huntington’s disease franchise and broader neurological disease pipeline focused on [...]
Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45
14/10/2026
-- Cohort 1 met the primary objectives of favorable safety and tolerability at the initial dose of 5 mg/kg -- -- ENTR-601-45 plasma exposures were consistent with those predicted based on juvenile non-human primate [...]
Orvida Pharma Announces FDA Acceptance of KM-023 (ontivatrep) into Rare Disease Evidence Principles Process for Olmsted Syndrome
14/10/2026
FDA’s Rare Disease Evidence Principles ( RDEP) process aims to provide greater speed and predictability in the review of therapies for rare diseases with significant unmet medical need Acceptance enables engagement with [...]
Matchpoint Therapeutics Expands Leadership Team with Appointment of John O’Malley, M.D., Ph.D., as Chief Medical Officer
14/10/2026
Dr. O’Malley brings deep immunology clinical development expertise, with previous leadership roles at CRISPR Therapeutics and Sanofi Appointment follows Matchpoint’s recent $150M Series B financing to advance pipeline [...]
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
14/10/2026
-- Company to receive ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 -- -- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027 -- BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- [...]
Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome
14/10/2026
FLINTLOCK Phase 2 clinical trial will evaluate the safety, tolerability, pharmacokinetics, and clinical efficacy of high-dose monoclonal antibody VYD2311 in adults aged 18-65 years with Long COVID or Post-Vaccination [...]

Pages